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Zebrafish is a vertebrate model organism widely used to study developmental and malignant hematopoiesis. All major mammalian blood cell lineages are present in zebrafish, and many genes and pathways involved in vertebrate hematopoiesis are conserved between fish and mammals [1] [2] [3] . The small size of zebrafish embryos, the ease of handling and culture, and the transparent nature of the embryonic and larval stages, make it an accessible, in vivo imaging-friendly vertebrate model. Additionally, early stage embryos are permeable to chemicals added to water, which makes them suitable for large scale pharmaceutical testing 4 . Toxicity to blood cells is one of the most common drug side effects 5, 6 ; current screening strategies rely on in vitro assays with limited readouts. Classical in vivo mammalian models, although very informative, are laborious and not suitable for high throughput experiments 7 8 . Here we report a novel zebrafish-based model for analyses of erythroid toxicity and regeneration.
Erythroid populations have been previously monitored using a Tg(gata1:dsRed) line driving expression from the gata1 promoter mostly expressed in progenitor cells 9 Figure 1D ). Consistent with our flow cytometry results, progenitor numbers increased noticeably in the CHT between 2 and 4 dpf ( Figure 1D ). Around 5 dpf, the stem and progenitor cells migrate from the CHT to the kidney marrow where the adult hematopoiesis takes place 12 . In line, gata1-positive progenitors slightly decreased in the CHT at 5 dpf ( Figure   1D ), whereas overall numbers increased (Online Supplementary Figure S2E Since we observed differences in required compound dosages, we investigated whether drugs differed with respect to their bioavailability following water uptake. We analyzed concentrations of irinotecan and topotecan in embryos treated from 32 hpf to 3 dpf and in the corresponding incubation media. The concentrations in the embryo increased proportionally with higher medium concentrations but remained in the ng/ml range despite very high concentrations in the medium (μg/ml range) (Online Supplementary Figure S4 ). Interestingly, irinotecan showed higher accumulation in the embryo than topotecan (Online Supplementary Figure S4B ). This result corresponds with our phenotypic analyses, indicating that higher concentrations of topotecan are needed for similar effects on erythroid cells.
Interestingly, when administered via injection into the yolk at 24 hpf, topotecan was at least equally potent as irinotecan at the same concentration ( Figure   2A -B and online Supplementary Figure S3H ). Therefore, bioavailability of different compounds during water exposure varies dependent on their different physical, chemical and biological properties, and should be routinely assessed when screening also larger sets of compounds.
Phenylhydrazine is a chemical known to cause hemolytic anemia through oxidization of hemoglobin and has been previously used in zebrafish. 13 
Compound exposure
Irinotecan (8 mM in DMSO stock solutions, ChemPacific Corporation) and topotecan (1.6 mM in DMSO stock solution, Sigma-Aldrich), were diluted in zebrafish E3 medium 1 . 10-12 embryos were incubated in 1.5 ml water with compound in a 24-well plate as indicated.
Phenylhydrazine (PHZ, Sigma-Aldrich, 1 mg/ml water stock solution) was diluted in the E3 medium to 1 µg/ml. Embryos were incubated in 24-well plates from 36 to 54 hpf and then washed 4 times with fresh E3 medium.
For irinotecan + PHZ experiments, embryos were incubated from 36 to 52 hpf in 1 µg/ml PHZ only, 1 µg/ml PHZ and 2 µM irinotecan, 2 µM irinotecan only or 0.1 % DMSO for control. At 52 hpf solutions were washed away and replaced with E3 or 2 µM irinotecan, respectively and analyzed at 4 dpf. For injection, irinotecan (32 µM), topotecan (32 µM) or DMSO (20%) as control respectively, were injected into the yolk sac of 24 hpf zebrafish embryos (drop size ~2nl). Embryos were kept in E3 medium and analyzed at 6 dpf. 
Bioanalytical compound uptake studies
Embryos were incubated in freshly prepared dilutions of irinotecan (1 and 5 µM) or topotecan (5 and 25 µM) from 36 hpf to 3 dpf. A sample of medium was taken at the beginning and at the end of the experiment. The embryos were washed 3 times with filtered E3 medium, the excess of water was removed and the embryos were frozen for analysis.
Concentrations of topotecan and irinotecan were determined by reversed phase HPLC tandem mass spectrometry. 100 µL of incubation medium were Medium and embryos probes were mixed for 30 s, centrifuged (6400g, 10min, 10 ºC) and 10 µL of the supernatant was injected into the LC-MS/MS system for analysis.
Chromatographic separation was performed on a Shimadzu UHPLC system linearly increased from 10 to 90 %, at 1.51 min, the percentage of B was maintained for 0.5 min. At 2 min, the initial conditions were re-established.
A calibration curve was constructed plotting analyte concentration vs. peak area ratios of the analyte/ internal standard measured in samples.
The assay was linear between 1 and 1000 ng/mL and the lower limit of quantification was 1ng/mL for both analytes.
Statistical analyses
Statistical analyses were performed with GraphPad Prism 6 software. Multiple samples were compared using Ordinary One-way ANOVA test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 Figure  S1 . Full images used for zoomed-in pictures in Figure 2D . 
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